Compare Cintas Corporation (CTAS) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cintas Corporation vs GSK plc — how do they compare? Cintas Corporation trades at $202.41 (market cap $79.86B), while GSK plc trades at $46.5 (market cap $91.88B). The key difference: GSK plc is the larger of the two by market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold Cintas Corporation for 125 Days and GSK plc for 93 Days on average.
| CTAS | GSK | |
|---|---|---|
Market Cap | $79.86B | $91.88B |
Volume | 1,323,583 | 7,730,529 |
Sector | Industrials | Health |
52-Week High | $216.53 | $61.18 |
52-Week Low | $163.55 | $43.24 |
Typical Hold Time | 125 Days | 93 Days |
Enterprise Value | $82.33B | $111.88B |
Dividend Yield | 1.03% | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cintas (CTAS) trades at $201.12, up 1.99% with a bullish technical signal. The company reported strong Q1 2027 results with revenue reaching $3.01 billion (10.9% growth) and earnings of $1.39 per share beating estimates. Fundamentals show robust profitability with 17.82% net margin and 41.25% ROE, though valuation ratios remain elevated at P/E 39.67. Recent guidance increases and consistent dividend growth support positive momentum.
The outlook remains positive with analyst consensus target of $234.60 (16.6% upside) and 40% buy ratings. Key risks include premium valuation multiples and potential economic sensitivity. The stock offers quality fundamentals but requires monitoring of margin sustainability and competitive pressures in the uniform services sector.
GSK trades at $46.54, down 1.02% with bearish technical signals but strong fundamentals including 29.73% ROE and consistent earnings beats. The company maintains robust profitability with 72.73% gross margins and is actively expanding its oncology pipeline through strategic partnerships. Recent developments include a $750M cancer therapy acquisition and advancing mRNA vaccine candidates.
GSK presents a mixed outlook with strong operational performance offset by technical weakness. Investment appeal lies in valuation multiples below industry averages and pipeline expansion, though risks include HIV patent expirations and manufacturing restructuring. Analyst consensus leans cautious with 55% hold ratings amid near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cintas Corporation
In its core uniform and facility services unit (78% of sales), Cintas provides uniform rental programs to businesses across the size spectrum, mostly in North America. The firm is by far the largest provider in the industry. Facilities products generally include the rental and sale of entrance mat, mops, shop towels, hand sanitizers, and restroom supplies. Cintas also runs a first aid and safety services business (11% of sales), a fire protection services business (7% of sales), and a uniform direct sales business (4% of sales).
Read more on CTAS →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
